X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (117) 117
humans (105) 105
once-daily lixisenatide (105) 105
type 2 diabetes (97) 97
diabetes mellitus, type 2 - drug therapy (91) 91
endocrinology & metabolism (91) 91
basal insulin (68) 68
diabetes (66) 66
hypoglycemic agents - therapeutic use (66) 66
double-blind (59) 59
insulin (57) 57
open-label (55) 55
glycemic control (54) 54
placebo-controlled trial (51) 51
female (45) 45
male (45) 45
glucagon (41) 41
glucose (40) 40
lixisenatide (40) 40
hypoglycemia (39) 39
glucagon-like peptide-1 (38) 38
glucagon-like peptide-1 receptor - agonists (38) 38
hypoglycemic agents - administration & dosage (38) 38
once-daily liraglutide (38) 38
peptides - therapeutic use (37) 37
middle aged (36) 36
liraglutide (35) 35
metformin (34) 34
clinical trials (32) 32
diabetes mellitus (31) 31
exenatide (31) 31
treatment outcome (31) 31
drug therapy, combination (30) 30
type 2 diabetes mellitus (30) 30
care and treatment (29) 29
diabetes mellitus, type 2 - blood (29) 29
hypoglycemic agents - adverse effects (29) 29
safety (29) 29
aged (28) 28
diabetes therapy (28) 28
glp-1 receptor agonist (28) 28
hypoglycemia - chemically induced (27) 27
pharmacology & pharmacy (27) 27
receptor agonist lixisenatide (27) 27
fixed-ratio combination (26) 26
insulin - therapeutic use (26) 26
drug therapy (25) 25
internal medicine (25) 25
blood glucose - metabolism (24) 24
insulin glargine (24) 24
blood glucose - drug effects (23) 23
dextrose (23) 23
glycated hemoglobin a - metabolism (23) 23
analysis (22) 22
efficacy (22) 22
glycosylated hemoglobin (22) 22
glycated hemoglobin a - analysis (21) 21
hypoglycemic agents (21) 21
exenatide twice (20) 20
hyperglycemia (20) 20
beta-cell function (19) 19
body weight (19) 19
glp-1 receptor agonists (19) 19
medicine, general & internal (19) 19
type-2 diabetes-mellitus (19) 19
diabetes mellitus, type 2 - metabolism (18) 18
metformin-treated patients (18) 18
peptides (18) 18
adult (17) 17
hemoglobin (17) 17
insulin - administration & dosage (17) 17
metformin - therapeutic use (17) 17
patients (17) 17
peptides - administration & dosage (17) 17
peptides - adverse effects (17) 17
therapy (17) 17
double-blind method (16) 16
glp (16) 16
glp-1 (16) 16
type-2 (16) 16
medicine & public health (15) 15
randomized controlled trials as topic (15) 15
dosage and administration (14) 14
drug administration schedule (14) 14
glucagon-like peptide 1 (14) 14
glucagon-like peptide-1 receptor (14) 14
original (14) 14
24-week (13) 13
getgoal-l (13) 13
open-label trial (13) 13
original article (13) 13
postprandial period (13) 13
research (13) 13
endocrinology (12) 12
glucagon-like peptide 1 - analogs & derivatives (12) 12
glycated hemoglobin a - drug effects (12) 12
hypoglycemic agents - pharmacology (12) 12
liraglutide - therapeutic use (12) 12
review (12) 12
to-target trial (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2018, Volume 20, Issue 11, pp. 2690 - 2694
Journal Article
Medicine, ISSN 0025-7974, 12/2018, Volume 97, Issue 51, pp. e13710 - e13710
Objective: We aimed to systematically evaluate the efficacy and safety of lixisenatide in patients with type 2 diabetes mellitus. Methods: PubMed, EMBASE,... 
METFORMIN | GLYCEMIC CONTROL | EXENATIDE TWICE | PLACEBO | GLP-1 RECEPTOR AGONISTS | ADD-ON | ONCE-DAILY LIXISENATIDE | meta-analysis | diabetes mellitus | OPEN-LABEL | MEDICINE, GENERAL & INTERNAL | lixisenatide | review | BASAL INSULIN | DOUBLE-BLIND | Type 2 diabetes | Clinical trials | Drug therapy | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 02/2015, Volume 31, Issue 2, pp. 204 - 211
Journal Article
Journal Article
Journal Article
American Heart Journal, ISSN 0002-8703, 2015, Volume 169, Issue 5, pp. 631 - 638.e7
Journal Article
Journal Article
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 11/2014, Volume 30, Issue 8, pp. 726 - 735
BackgroundThis study assessed the efficacy and safety of the once-daily glucagon-like peptide-1 receptor agonist, lixisenatide, in Asian patients with type 2... 
glucagon‐like peptide‐1 (GLP‐1) receptor agonists | lixisenatide | Asia | type 2 diabetes mellitus (T2DM) | Glucagon-like peptide-1 (GLP-1) receptor agonists | Type 2 diabetes mellitus (T2DM) | Lixisenatide | EFFICACY | SAFETY | ONCE-DAILY LIXISENATIDE | EXENATIDE | PREVALENCE | HYPERGLYCEMIA | GLUCAGON-LIKE PEPTIDE-1 | glucagon-like peptide-1 (GLP-1) receptor agonists | BASAL INSULIN | GLUCOSE | ENDOCRINOLOGY & METABOLISM | RECEPTOR AGONIST LIXISENATIDE | Glycated Hemoglobin A - analysis | Metformin - therapeutic use | Nausea - chemically induced | Drug Resistance, Multiple | Humans | Middle Aged | Male | Malaysia | Diabetes Mellitus, Type 2 - metabolism | Thailand | Metformin - adverse effects | Drug Therapy, Combination - adverse effects | China | Adult | Female | Hypoglycemia - chemically induced | Drug Resistance | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Hyperglycemia - prevention & control | Double-Blind Method | Sulfonylurea Compounds - therapeutic use | Receptors, Glucagon - metabolism | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Glucagon-Like Peptide-1 Receptor | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Peptides - therapeutic use | Type 2 diabetes | Glucose metabolism | Care and treatment | Glucagon | Clinical trials | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Insulin | Diabetes | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2017, Volume 19, Issue 9, pp. 1317 - 1321
Chronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes‐related complications. We conducted a pooled analysis of... 
glycaemic variability | type 2 diabetes | insulin | lixisenatide | BASAL INSULIN | RECEPTOR AGONISTS | WELL | ONCE-DAILY LIXISENATIDE | ENDOCRINOLOGY & METABOLISM | PLASMA-GLUCOSE | 24-WEEK | Glycated Hemoglobin A - analysis | Follow-Up Studies | Humans | Middle Aged | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemia - physiopathology | Hyperglycemia - physiopathology | Hypoglycemia - chemically induced | Drug Resistance | Hypoglycemic Agents - therapeutic use | Severity of Illness Index | Hyperglycemia - prevention & control | Reproducibility of Results | Blood Glucose - analysis | Double-Blind Method | Diabetes Mellitus, Type 2 - blood | Intention to Treat Analysis | Blood Glucose Self-Monitoring | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Insulin - therapeutic use | Peptides - adverse effects | Peptides - therapeutic use | Cohort Studies | Type 2 diabetes | Medical research | Hyperglycemia | Care and treatment | Blood sugar | Medicine, Experimental | Insulin | Body mass index | Diabetes mellitus | Clinical trials | Data processing | Glucose | Diabetes | Hypoglycemia | Index Medicus | Life Sciences | Human health and pathology | Endocrinology and metabolism
Journal Article